Personalized cancer vaccines are an emerging approach in precision cancer treatment. Unlike preventive vaccines that protect against infections, these therapeutic vaccines are designed for an individual after cancer has been diagnosed. The goal is to train the immune system to recognize specific molecular features found in the person's tumor and attack cancer cells carrying those features. The approach is particularly interesting because the vaccine can be customized rather than using exactly the same formulation for every patient.
A personalized cancer vaccine is created using information obtained from an individual's tumor.
Cancer cells can contain mutations that are different from those found in healthy cells. Some of these mutations create abnormal proteins or protein fragments called neoantigens. Because neoantigens can be unique to a particular tumor, they may provide useful targets for an immune response.
The vaccine is designed to present selected neoantigens to the immune system so that cancer-fighting T cells can recognize them more effectively.
The process generally begins with a biopsy or surgical tumor sample.
Scientists analyze the cancer tissue and compare its genetic information with normal tissue. DNA and RNA sequencing can help identify mutations that are specific to the cancer.
This information provides the molecular blueprint needed to design an individualized vaccine.
Not every mutation found in a tumor makes a useful vaccine target.
Researchers use computational and laboratory methods to identify mutations that are likely to produce abnormal proteins that can be recognized by the immune system.
The strongest candidates are selected based on factors such as whether the mutated protein is produced by the tumor and whether fragments can potentially be presented to T cells.
Once the target neoantigens have been selected, a personalized vaccine is produced.
Different vaccine platforms are being investigated, including:
mRNA approaches can encode multiple tumor-specific neoantigens within a single vaccine formulation.
After administration, the vaccine provides instructions or protein fragments representing selected tumor neoantigens.
With mRNA vaccines, antigen-presenting cells can take up the mRNA and produce the encoded neoantigen proteins. These proteins are then processed and displayed through major histocompatibility complex (MHC) molecules.
This presentation helps the immune system recognize the selected cancer targets.
The objective is to stimulate cancer-specific CD4 and CD8 T-cell responses.
CD8 T cells can directly attack cells displaying the relevant cancer-associated targets, while CD4 T cells can help coordinate and support broader immune activity.
Some vaccine strategies are also designed to encourage immune memory, potentially allowing the immune system to respond if cancer cells carrying the same targets appear again.
Traditional cancer treatments generally target cancer based on its location, tissue type, or broader biological characteristics.
Personalized cancer vaccines attempt to identify molecular targets unique to an individual's tumor.
This creates the possibility of highly individualized treatment in which the vaccine composition differs from one patient to another.
Personalized cancer vaccines are being investigated across several cancer types.
Research has included:
The strongest evidence remains under investigation, and results have varied between cancer types and clinical studies.
mRNA has attracted substantial attention because it can encode multiple neoantigens in a relatively flexible vaccine platform.
An mRNA vaccine does not permanently alter a person's DNA. Instead, the mRNA provides temporary instructions that cells use to produce selected proteins before the molecule is naturally broken down.
Several personalized mRNA cancer vaccines are currently being investigated in clinical research.
These vaccines are generally being developed as therapeutic cancer treatments, meaning they are intended for people who already have cancer or have undergone treatment for cancer.
They are different from preventive vaccines such as HPV and hepatitis B vaccines, which can reduce the risk of certain cancers by preventing infections that contribute to cancer development.
One important research area involves using personalized cancer vaccines after surgery.
Surgery can remove visible cancer, but microscopic cancer cells may remain and potentially cause recurrence. A vaccine may be used to stimulate immune cells against tumor-specific neoantigens in an attempt to eliminate residual cancer cells.
Research in triple-negative breast cancer has reported persistent vaccine-induced T-cell responses in a small early-stage study, although larger studies are needed to determine how consistently these immune responses translate into improved clinical outcomes.
Researchers are also studying personalized vaccines in combination with other cancer treatments.
Potential combinations include:
The reasoning is that vaccines may help identify the cancer targets while another treatment may improve the ability of immune cells to attack the tumor.
Personalized vaccination is scientifically promising but technically complex.
Major challenges include:
A 2026 review noted that early clinical studies have demonstrated feasibility and immune responses, but consistent clinical benefit has not yet been established across tumor types.
Personalized neoantigen cancer vaccines remain largely within clinical research rather than being established standard treatment for most cancers.
Specific cancer vaccines and vaccine-based therapies may be studied in clinical trials, and eligibility depends on the cancer type, stage, previous treatments, biomarkers, and study requirements.
A personalized cancer vaccine should therefore not be viewed as a universally established replacement for standard cancer treatment.
Personalized cancer vaccines represent a developing form of precision immunotherapy designed around the unique molecular characteristics of an individual's tumor. The process typically begins with a tumor sample, followed by DNA or RNA sequencing to identify mutations that may produce cancer-specific neoantigens. Researchers then select promising targets and create a vaccine containing instructions or protein fragments designed to present those targets to the immune system.
Once administered, the vaccine is intended to activate cancer-specific immune responses, particularly T cells. With mRNA-based approaches, antigen-presenting cells can produce the selected neoantigens and display them to immune cells. The resulting immune response is intended to recognize and attack cancer cells carrying the same molecular targets.